TECTONIC THERAPEUTIC, INC. Deferred Costs, Noncurrent
TECTONIC THERAPEUTIC, INC. (TECX) had Deferred Costs, Noncurrent of $0 as of 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredCosts · last filed 2025-03-20
- 2024-12-31: Deferred Costs, Noncurrent $0.00.
- 2024-09-30: Deferred Costs, Noncurrent $0.00.
- 2024-06-30: Deferred Costs, Noncurrent $0.00.
- 2023-12-31: Deferred Costs, Noncurrent $669.00K.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-20 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 |
| 2023-12-31 | $669.00K 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |